These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 15533864)
1. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Van Lenten BJ; Wagner AC; Navab M; Anantharamaiah GM; Hui EK; Nayak DP; Fogelman AM Circulation; 2004 Nov; 110(20):3252-8. PubMed ID: 15533864 [TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Sherman CB; Peterson SJ; Frishman WH Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699 [TBL] [Abstract][Full Text] [Related]
3. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455 [TBL] [Abstract][Full Text] [Related]
5. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Geiler J; Michaelis M; Naczk P; Leutz A; Langer K; Doerr HW; Cinatl J Biochem Pharmacol; 2010 Feb; 79(3):413-20. PubMed ID: 19732754 [TBL] [Abstract][Full Text] [Related]
6. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Van Lenten BJ; Wagner AC; Anantharamaiah GM; Garber DW; Fishbein MC; Adhikary L; Nayak DP; Hama S; Navab M; Fogelman AM Circulation; 2002 Aug; 106(9):1127-32. PubMed ID: 12196340 [TBL] [Abstract][Full Text] [Related]
7. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Han CY; Chiba T; Campbell JS; Fausto N; Chaisson M; Orasanu G; Plutzky J; Chait A Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1806-13. PubMed ID: 16709944 [TBL] [Abstract][Full Text] [Related]
8. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Lee N; Wong CK; Chan PK; Lun SW; Lui G; Wong B; Hui DS; Lam CW; Cockram CS; Choi KW; Yeung AC; Tang JW; Sung JJ Clin Infect Dis; 2007 Sep; 45(6):723-31. PubMed ID: 17712756 [TBL] [Abstract][Full Text] [Related]
9. Secretion of bioactive interleukin-6 and tumor necrosis factor-alpha proteins from primary cultured human fetal membrane chorion cells infected with influenza virus. Uchide N; Suzuki A; Ohyama K; Bessho T; Toyoda H Placenta; 2006; 27(6-7):678-90. PubMed ID: 16122792 [TBL] [Abstract][Full Text] [Related]
10. Infection of human retinal pigment epithelial cells with influenza A viruses. Michaelis M; Geiler J; Klassert D; Doerr HW; Cinatl J Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5419-25. PubMed ID: 19553611 [TBL] [Abstract][Full Text] [Related]
12. ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer. Cedó L; García-León A; Baila-Rueda L; Santos D; Grijalva V; Martínez-Cignoni MR; Carbó JM; Metso J; López-Vilaró L; Zorzano A; Valledor AF; Cenarro A; Jauhiainen M; Lerma E; Fogelman AM; Reddy ST; Escolà-Gil JC; Blanco-Vaca F Sci Rep; 2016 Nov; 6():36387. PubMed ID: 27808249 [TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. Van Lenten BJ; Wagner AC; Jung CL; Ruchala P; Waring AJ; Lehrer RI; Watson AD; Hama S; Navab M; Anantharamaiah GM; Fogelman AM J Lipid Res; 2008 Nov; 49(11):2302-11. PubMed ID: 18621920 [TBL] [Abstract][Full Text] [Related]
14. Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action. Getz GS; Wool GD; Reardon CA Curr Opin Lipidol; 2009 Jun; 20(3):171-5. PubMed ID: 19373084 [TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976 [TBL] [Abstract][Full Text] [Related]
16. Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Khaitov MR; Laza-Stanca V; Edwards MR; Walton RP; Rohde G; Contoli M; Papi A; Stanciu LA; Kotenko SV; Johnston SL Allergy; 2009 Mar; 64(3):375-86. PubMed ID: 19175599 [TBL] [Abstract][Full Text] [Related]
17. Phenotypic alterations in type II alveolar epithelial cells in CD4+ T cell mediated lung inflammation. Gereke M; Gröbe L; Prettin S; Kasper M; Deppenmeier S; Gruber AD; Enelow RI; Buer J; Bruder D Respir Res; 2007 Jul; 8(1):47. PubMed ID: 17610738 [TBL] [Abstract][Full Text] [Related]
18. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146 [TBL] [Abstract][Full Text] [Related]